{"success":true,"data":{"pressRelease":{"id":"17175","rtpr_id":"nGNX9Yy38L","ticker":"ATRA","exchange":"NASDAQ","all_tickers":["ATRA"],"title":"ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm","author":"Globe Newswire","published_at":"2026-05-01T13:54:56.097Z","article_body":"LOS ANGELES, May 01, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm\n(https://www.globenewswire.com/Tracker?data=pNGxBn1cTUWJJGGS-I5yMjf_1xxM2RPhjrDJXnLcU6aCqv6-iW6RF8S6N9Za_mUo68TKOjfMNgqbu_GMPbC168rYtwEwIZLPfDDTnKBwms4=),\na national shareholder rights litigation firm, reminds investors of a class\naction lawsuit against Atara Biotherapeutics, Inc. (“Atara” or “the\nCompany”) (NASDAQ: ATRA\n(https://www.globenewswire.com/Tracker?data=t4ovPXdvYHJayy_DafmJkOBOY6Oa--3Hb365KSONLmfE-ye5M1NtcG5UAFcsqjEcpppJVkGO_MAPp82DVfAMN9kazRJXtAk7qvZBSTDNuFY=))\nviolations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and\nRule 10b-5 promulgated thereunder by the U.S. Securities and Exchange\nCommission.\n\nInvestors who purchased the Company’s securities between May 20, 2024 and\nJanuary 9, 2026, inclusive (the “Class Period”), are encouraged to contact\nthe firm before May 22, 2026.\n\nIf you are a shareholder who suffered a loss, click here to participate\n(https://www.globenewswire.com/Tracker?data=YALj1ZDPVt3wNJdp_03VLxBEcoEojRtEu3ZWZrBZB21uir0bv3hBZX31bZ8Dn2xdCRoLMSImNLOGjSQq-2-Ol-BbGn1FBnfxOjasNB5u41uiHmbh-Jme8MmnqbKMw3moGgixveO2e4PbdnJN1E0RN37YYhjkvTIev6VgUiIi9g0=).\n\nWe also encourage you to contact Brian Schall of the Schall Law Firm, 2049\nCentury Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to\ndiscuss your rights free of charge. You can also reach us through the firm's\nwebsite at www.schallfirm.com, or by email at bschall@schallfirm.com.\n\nThe class, in this case, has not yet been certified, and until certification\noccurs, you are not represented by an attorney. If you choose to take no\naction, you can remain an absent class member.\n\nAccording to the Complaint, the Company made false and misleading statements\nto the market. Atara suffered from manufacturing problems and deficiencies in\nits ALLELE study which made it unlikely that the FDA would approve its BLA for\ntabelecleucel. The Company overstated the prospects of tabelecleucel. The\nCompany was subjected to a higher risk of regulatory action based on its\nmanufacturing issues. Based on these facts, the Company’s public statements\nwere false and materially misleading throughout the class period. When the\nmarket learned the truth about Atara, investors suffered damages.\n\nJoin the case\n(https://www.globenewswire.com/Tracker?data=apcUu_ob8PTM_azyAHl1QDwvc6WP1ZuwYXTkPyTcOuGAuI0lXtyTOXT4FFTPRuDzOND_z4uqGEy5Dv5jmGQgSPmGiJS-sbHoXguRyOrPJu5AAafovdGNRvBSvkSqUukZPKxJHYr62StF9PunzNEx1Q==)\nto recover your losses\n\nThe Schall Law Firm represents investors around the world and specializes in\nsecurities class action lawsuits and shareholder rights litigation.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.        \n\nCONTACT:\n\nThe Schall Law Firm\nBrian Schall, Esq.,\nwww.schallfirm.com\nOffice: 310-301-3335\ninfo@schallfirm.com\n\nSOURCE:\n\nThe Schall Law Firm\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/60f84371-8ef5-454a-ab60-63e56a837741)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9Yy38L","title":"ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm","author":"Globe Newswire","ticker":"ATRA","created":"2026-05-01T13:54:56.097Z","tickers":["ATRA"],"exchange":"NASDAQ","article_body":"LOS ANGELES, May 01, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm\n(https://www.globenewswire.com/Tracker?data=pNGxBn1cTUWJJGGS-I5yMjf_1xxM2RPhjrDJXnLcU6aCqv6-iW6RF8S6N9Za_mUo68TKOjfMNgqbu_GMPbC168rYtwEwIZLPfDDTnKBwms4=),\na national shareholder rights litigation firm, reminds investors of a class\naction lawsuit against Atara Biotherapeutics, Inc. (“Atara” or “the\nCompany”) (NASDAQ: ATRA\n(https://www.globenewswire.com/Tracker?data=t4ovPXdvYHJayy_DafmJkOBOY6Oa--3Hb365KSONLmfE-ye5M1NtcG5UAFcsqjEcpppJVkGO_MAPp82DVfAMN9kazRJXtAk7qvZBSTDNuFY=))\nviolations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and\nRule 10b-5 promulgated thereunder by the U.S. Securities and Exchange\nCommission.\n\nInvestors who purchased the Company’s securities between May 20, 2024 and\nJanuary 9, 2026, inclusive (the “Class Period”), are encouraged to contact\nthe firm before May 22, 2026.\n\nIf you are a shareholder who suffered a loss, click here to participate\n(https://www.globenewswire.com/Tracker?data=YALj1ZDPVt3wNJdp_03VLxBEcoEojRtEu3ZWZrBZB21uir0bv3hBZX31bZ8Dn2xdCRoLMSImNLOGjSQq-2-Ol-BbGn1FBnfxOjasNB5u41uiHmbh-Jme8MmnqbKMw3moGgixveO2e4PbdnJN1E0RN37YYhjkvTIev6VgUiIi9g0=).\n\nWe also encourage you to contact Brian Schall of the Schall Law Firm, 2049\nCentury Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to\ndiscuss your rights free of charge. You can also reach us through the firm's\nwebsite at www.schallfirm.com, or by email at bschall@schallfirm.com.\n\nThe class, in this case, has not yet been certified, and until certification\noccurs, you are not represented by an attorney. If you choose to take no\naction, you can remain an absent class member.\n\nAccording to the Complaint, the Company made false and misleading statements\nto the market. Atara suffered from manufacturing problems and deficiencies in\nits ALLELE study which made it unlikely that the FDA would approve its BLA for\ntabelecleucel. The Company overstated the prospects of tabelecleucel. The\nCompany was subjected to a higher risk of regulatory action based on its\nmanufacturing issues. Based on these facts, the Company’s public statements\nwere false and materially misleading throughout the class period. When the\nmarket learned the truth about Atara, investors suffered damages.\n\nJoin the case\n(https://www.globenewswire.com/Tracker?data=apcUu_ob8PTM_azyAHl1QDwvc6WP1ZuwYXTkPyTcOuGAuI0lXtyTOXT4FFTPRuDzOND_z4uqGEy5Dv5jmGQgSPmGiJS-sbHoXguRyOrPJu5AAafovdGNRvBSvkSqUukZPKxJHYr62StF9PunzNEx1Q==)\nto recover your losses\n\nThe Schall Law Firm represents investors around the world and specializes in\nsecurities class action lawsuits and shareholder rights litigation.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.        \n\nCONTACT:\n\nThe Schall Law Firm\nBrian Schall, Esq.,\nwww.schallfirm.com\nOffice: 310-301-3335\ninfo@schallfirm.com\n\nSOURCE:\n\nThe Schall Law Firm\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/60f84371-8ef5-454a-ab60-63e56a837741)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-01T13:54:56.127558338Z","server_sent_at_ms":1777643696127},"received_at":"2026-05-01T13:54:58.649Z","source_url":"https://www.globenewswire.com/news-release/2026/04/28/3282816/0/en/atra-investors-have-opportunity-to-lead-atara-biotherapeutics-inc-securities-fraud-lawsuit-with-the-schall-law-firm.html"},"analysis":{"id":"12649","press_release_id":"17175","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"The Schall Law Firm issued a solicitation for investors to lead a class action lawsuit against Atara Biotherapeutics regarding alleged securities fraud.\n\nThe complaint alleges that Atara made false statements regarding manufacturing problems in its ALLELE study and overstated the prospects for tabelecleucel approval.\n\nThe class has not yet been certified, and investors who purchased securities between May 20, 2024, and January 9, 2026, are encouraged to contact the firm before May 22, 2026.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney.","namedEntities":{"people":[{"name":"Brian Schall","role":"Attorney"}],"products":["tabelecleucel","ALLELE study"],"companies":[{"name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","relationship":"defendant"},{"name":"The Schall Law Firm","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by The Schall Law Firm. The class has not yet been certified and the release serves primarily to recruit a lead plaintiff."},"tickerRelevance":{"others":[],"primary":"ATRA"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"eventGravity":"law-firm-solicitation","classCertified":false,"issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"The Schall Law Firm issued a solicitation for investors to lead a class action lawsuit against Atara Biotherapeutics regarding alleged securities fraud.\n\nThe complaint alleges that Atara made false statements regarding manufacturing problems in its ALLELE study and overstated the prospects for tabelecleucel approval.\n\nThe class has not yet been certified, and investors who purchased securities between May 20, 2024, and January 9, 2026, are encouraged to contact the firm before May 22, 2026.","key_figures":{},"named_entities":{"people":[{"name":"Brian Schall","role":"Attorney"}],"products":["tabelecleucel","ALLELE study"],"companies":[{"name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","relationship":"defendant"},{"name":"The Schall Law Firm","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-01T14:26:50.272Z","global_importance":15,"audience_relevance":10,"importance_components":{"eventGravity":"law-firm-solicitation","classCertified":false,"issuerAuthored":false}},"durationMs":136551,"modelName":"glm-4.7"}}